Cost Comparison and Selection Guide for Imported vs. Domestic IVF Ovulation Induction Medications in China

Opening: Real Consultation Scenario

🏥 Clinic Scenario A 32-year-old woman with AMH 1.8 ng/mL and antral follicle count (AFC) of 10 asks at a reproductive center: "Doctor, should I use imported or domestic drugs for ovulation induction? What is the real difference between imported Gonal-f and domestic Lishenbao? Why do some sisters only spend three to four thousand, while I have to spend over ten thousand?"

1. Direct Answer: How Big is the Cost Difference Between Imported and Domestic Ovulation Induction Drugs?

The cost of ovulation induction drugs is one of the most variable parts of an IVF cycle. Taking commonly used recombinant FSH (follicle-stimulating hormone) as an example, the price difference per vial between imported and domestic brands is about 1.5 to 3 times. However, the final total cycle cost also depends on the total dosage, the type of protocol, and whether other medications are combined.

* Price ranges are compiled based on publicly available prices from domestic public reproductive centers and major pharmacies in 2024‑2025. Actual prices may vary due to regional differences, procurement channels, and medical insurance policies.

Key Conclusion: The cycle cost of domestic drugs is typically 40% to 60% of that of imported drugs. However, cost is not the only deciding factor—clinical pregnancy rate, follicle uniformity, ovarian response, and the patient's own endocrine status are equally critical.

2. Why is There Such a Big Price Difference Between Imported and Domestic Drugs?

The price difference mainly comes from four aspects:

• R&D and Patent Costs: Gonal-f (Merck Serono) and Puregon (Merck Sharp & Dohme) are original biologics with high initial R&D investment and different pricing strategies during the patent period. Domestic Lishenbao (Livzon) and Jinsaiheng (GeneScience) are biosimilars with relatively lower R&D costs.
• Production Process and Purity: Imported recombinant FSH uses CHO cell expression systems, with glycosylation closer to natural FSH and batch-to-batch stability verified over a longer period. Domestic counterparts have significantly improved their processes in recent years, but some micro-structural differences still exist.
• Supply Chain and Channels: Imported drugs go through import tariffs, cold chain logistics, and distribution layers from overseas factories to domestic end-users, driving up the final price. Domestic drugs have a shorter supply chain, making costs more controllable.
• Clinical Data Accumulation: Imported drugs have accumulated decades of large-scale clinical data globally. Doctors are more familiar with their response patterns in different populations, and this "experience premium" is also reflected in the pricing.

3. How Do Doctors Choose Between Imported and Domestic?

When prescribing ovulation induction drugs, reproductive doctors mainly base their decisions on the following clinical logic, not just the price:

4. Details Most Easily Overlooked

When focusing on "imported vs. domestic," the following details are often underestimated but significantly impact total cost and treatment experience:

• Type of Ovulation Induction Protocol: Antagonist protocols typically require 10%–20% less total medication than long protocols, correspondingly reducing costs. Regardless of whether imported or domestic, the protocol itself sometimes has a greater impact on total cost than the drug brand.
• Combination Medication Costs: Ovulation induction cycles often require combining LH (urinary/recombinant LH), growth hormone (GH), GnRH antagonists, etc. Imported LH (e.g., Luveris) costs 600–900 RMB per vial, while domestic LH options are limited. This part of the cost is easily overlooked.
• Medical Insurance Reimbursement Differences: Since 2024, regions like Beijing, Shanghai, and Zhejiang have included some ovulation induction drugs in medical insurance (Category B), but reimbursement rates and drug lists vary by location. Imported drugs generally have lower reimbursement rates than domestic ones in most areas, potentially widening the out-of-pocket gap.
• Handling Leftover Medication: Small doses of medication (e.g., half a vial of Gonal-f) are often left over in ovulation induction cycles. Some hospitals do not support returns or sharing, leading to waste. Domestic drugs have a lower unit price, so the absolute loss from waste is smaller.

5. Common Pitfalls to Avoid

6. Panorama of Factors Affecting Cost

Besides the drug brand, the following factors also determine the total expenditure during the ovulation induction phase:

• Weight and BMI: Higher body weight generally requires a higher total FSH dose. Patients with BMI >28 kg/m² may need 30%–50% more medication than those with normal weight.
• PCOS vs. Non-PCOS: Patients with Polycystic Ovary Syndrome are sensitive to FSH and require lower total doses but may need anti-androgen medications; non-PCOS patients have relatively stable dosage requirements.
• Previous Surgical History: After ovarian cystectomy or endometrioma removal, ovarian reserve declines, requiring higher FSH doses.
• Hospital Level and Procurement Channels: Large reproductive centers have lower drug markup rates due to high procurement volumes. Some private institutions may charge additional medication management fees, making the same drug 20%–40% more expensive than in public hospitals.

7. Frequently Asked Questions (Q&A)

Q1: Are domestic ovulation induction drugs really as effective as imported ones?

For patients with normal ovarian reserve (AMH 1.5–4 ng/mL, AFC 7–15) and age ≤37, domestic recombinant FSH (Lishenbao, Jinsaiheng) shows no significant difference from imported drugs in terms of oocyte yield, MII oocyte rate, and high-quality embryo rate. However, for poor ovarian responders or older individuals, imported drugs have more robust batch stability and clinical data support, making them the preferred choice for doctors.

Q2: Can I request to use only domestic or only imported drugs?

You can express your preference, but the final protocol is determined by the doctor based on your ovarian function, hormone levels, and ultrasound results. The doctor will explain why a particular type is recommended—for example, "Your AMH is low; imported drugs allow for more precise dosage control" or "Your ovarian function is excellent; domestic drugs are sufficient."

Q3: Are ovulation induction drugs covered by medical insurance?

As of 2025, provinces such as Beijing, Shanghai, Zhejiang, Jiangsu, and Guangdong have included some ovulation induction drugs in the Category B medical insurance list, with reimbursement rates of about 40%–70%. However, imported drugs generally have lower reimbursement rates than domestic ones (some imported drugs are not even on the list). Check with the hospital's insurance office for the specific reimbursement status of the drugs before treatment.

Q4: How many days does ovulation induction usually take? What is the total cost?

The typical duration of ovulation induction is 10–14 days. Total dosage varies from 75 to 300 IU per day. Based on a daily dose of 150 IU, one cycle requires about 10–20 vials (75 IU/vial). The total cost for an imported protocol ranges from 8,000 to 18,000 RMB, for a domestic protocol from 3,500 to 9,000 RMB, and for a mixed protocol falls somewhere in between.

Q5: Can imported and domestic drugs be mixed?

Yes, and it is a common clinical practice. For example, using domestic HMG early to save costs, then switching to imported recombinant FSH when follicles reach 14 mm in diameter to improve uniformity. Mixed protocols require the doctor to make dynamic adjustments based on daily ultrasound and hormone results.

8. Practitioner's Observation (From a Patient Education Specialist's Perspective)

In years of patient counseling, I have observed two typical phenomena:

• Anxiety Caused by Information Asymmetry: Many patients see inaccurate information online, such as "imported drugs double the pregnancy rate," and actively request imported drugs, even experiencing psychological stress due to financial pressure. In reality, for young patients with normal ovarian function, domestic drugs can achieve the desired results.
• Neglecting Medication Adherence: Regardless of whether drugs are imported or domestic, correct and timely injections and monitoring are the keys to outcomes. Some patients reduce doses on their own due to cost concerns or miss injections due to pain, leading to poor follicle development and eventual cycle cancellation. These issues are more critical than the drug brand.

It is recommended that first-cycle patients: first complete a basic assessment (AMH, AFC, FSH, LH, E2, semen analysis), then thoroughly discuss the protocol type and drug choice with the doctor, rather than focusing solely on the brand.

9. When is it Suitable/Unsuitable to Use Domestic Ovulation Induction Drugs?

Suitable Candidates for Domestic Drugs

• Age ≤37, AMH ≥1.5 ng/mL, AFC ≥7
• No history of ovarian surgery, no severe endometriosis
• No previous history of failed cycle or cancellation with domestic drugs
• Sensitive to treatment costs and wishes to reduce total cycle expenditure
• Willing to undergo daily monitoring, allowing the doctor to flexibly adjust the protocol based on response

Unsuitable Candidates for Using Only Domestic Drugs

• AMH <1.0 ng/mL, AFC <5 (poor ovarian responders)
• Age ≥40, or previous follicle development arrest with domestic drugs
• Requires concurrent use of recombinant LH (e.g., Luveris) or growth hormone for combination therapy
• Doctor assesses that maximum batch stability is needed to ensure follicle uniformity

10. How to Choose: A Decision Framework

Faced with the choice between imported and domestic, you can clarify your thinking by following these steps:

1. Step 1: Complete a Basic Assessment — AMH, AFC, FSH, LH, E2, thyroid function, vitamin D. Determine your ovarian reserve grade.
2. Step 2: Determine the Type of Ovulation Induction Protocol — Antagonist protocol? Long protocol? Mild stimulation? The protocol's impact on total dosage can sometimes be greater than the brand.
3. Step 3: Discuss Drug Choice with Your Doctor — Ask directly: "Based on my situation, what is the expected difference in oocyte yield and pregnancy rate between domestic and imported drugs? Which do you recommend?"
4. Step 4: Calculate the Comprehensive Cost — Consider not only the drug cost but also the number of monitoring visits, injection fees, potential waste from leftover medication, and medical insurance reimbursement rates.
5. Step 5: Keep a Medication Record — Regardless of which drug you choose, record the daily dose, follicle growth rate, and hormone level changes to provide a reference for subsequent cycles.

11. Risk Reminders and Next Steps

Suggested Next Steps: If you are preparing to start an IVF cycle, it is recommended to first complete a comprehensive reproductive baseline assessment (blood draw on day 2-4 of menstruation + vaginal ultrasound) and bring all previous test reports to the reproductive center for consultation. The choice of ovulation induction drugs is just one part of the overall treatment. Developing an individualized protocol is far more important than agonizing over "imported vs. domestic."

This content is based on general knowledge in the assisted reproductive technology field and does not constitute personal medical advice. Please follow your doctor's evaluation for specific medication plans.